Investor Relations

Advanced therapies for the sports medicine and severe burn care markets

Investor Relations

Press Releases

Webcast Alert: Aastrom Biosciences Announces Its First Quarter Investor Conference Call

November 4, 2005 at 12:00 AM EST
Webcast Alert: Aastrom Biosciences Announces Its First Quarter Investor Conference Call

Ann Arbor, MI, November 4, 2005 -- Aastrom Biosciences (NASDAQ: ASTM) announces the following Webcast:

What: Aastrom Biosciences First Quarter Fiscal Year End 2006 Investor Conference Call

When: Wednesday, November 9, 2005 @ 11:00 AM Eastern

Where: http://www.investorcalendar.com/IC/CEPage.asp?ID=96864

How:

  • For live over the Internet access, simply log on to the web at the address above.
  • For phone access, interested parties should call toll-free (877) 407-9205 before the start of the call to register and identify themselves as registrants of the "Aastrom Conference Call". Any registered caller on the toll-free line may ask for call operator for directions to be placed in the queue for the Question & Answer session.
  • To download the podcast, simply log on to the web at the address above.

Contact: Kris Maly, Investor Relations Department, (734) 930-5777 or mail@aastrom.com

If you are unable to participate during the live webcast, the call will be available for replay at http://www.investorcalendar.com/ for 60 days.

Aastrom Biosciences, Inc. (Nasdaq: ASTM) is developing patient-specific products for the repair or regeneration of human tissues, utilizing the Company's proprietary adult stem cell technology. Aastrom's strategic position in the tissue regeneration sector is enabled by its proprietary Tissue Repair Cells (TRCs), a mix of bone marrow-derived adult stem and progenitor cells manufactured in the AastromReplicell® System, an industry-unique automated cell production system. TRCs are the core component of the products Aastrom is developing for severe bone fractures, ischemic vascular disease, jaw reconstruction and spine fusion, with Phase I/II level clinical trials active in the U.S. and EU for some of these indications.

For more information, visit Aastrom's website at www.aastrom.com.

Day High:
Day Low:
Volume:
on
Data Provided by Refinitiv. Minimum 15 minutes delayed.